The findings revealed that LB CD2 did not affect the frequency of severe OM, taking into account the statistical restriction of the current trial (the targeted accrual was not met due to the absence of LB CD2 supply) (intervention versus control arm: 40.6% versus 41.6%, respectively). This evidence concerns the gene CD2 and ocular melanoma.